Press Releases

Initiator Phama A/S (“Initiator” or the “Company”) announced on May 19, 2025, that the board had resolved on a rights issue of SEK 56 million (the “Rights Issue”). In connection with the Rights Issue, The Company has prepared a Memorandum and a Disclosure Document.

Initiator Phama A/S (“Initiator” eller “Bolaget”) offentliggjorde den 19 maj 2025 att styrelsen beslutat om en företrädesemission om 56 MSEK (“Företrädesemissionen”). I samband med Företrädesemissionen har Bolaget upprättat ett memorandum och ett informationsdokument.

Company reg. (CVR) no. 37663808

Initiator Pharma updates the timeline for the rights issue, the record date is on June 10, 2025 and the subscription period runs from and including June 12, 2025 up to and including June 26, 2025.

Initiator Pharma uppdaterar tidplanen för företrädesemissionen, avstämningsdagen är den 10 juni 2025 och teckningsperioden löper från och med den 12 juni 2025 till och med den 26 juni 2025.

The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 23 May 2025 at 10.00 AM CEST.

Company reg. (CVR) no. 37663808

Styrelsen i Initiator Pharma A/S (“Initiator” eller “Bolaget”) har idag, med stöd av bemyndigandet från årsstämman den 24 maj 2024, beslutat om en nyemission av aktier med företrädesrätt för befintliga aktieägare om cirka 56,2 MSEK före emissionskostnader (”Företrädesemissionen”). Bolaget har erhållit teckningsåtaganden från befintliga aktieägare, inklusive Linc och MAC Clinical Research, samt från styrelseledamöter och ledning, om cirka 15 MSEK, motsvarande cirka 27 procent av Företrädesemissionen. Därutöver har Bolaget ingått garantiåtaganden med befintliga aktieägare och externa investerare om sammanlagt cirka 33 MSEK, motsvarande cirka 59 procent av Företrädesemissionen. Företrädesemissionen är således säkerställd till cirka 86 procent genom teckningsåtaganden och garantiåtaganden om totalt cirka 48 MSEK.

The board of directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today, based on the authorisation from the general meeting held on 24 May 2024, resolved on a new issue of shares with pre-emption rights for the Company’s existing shareholders amounting to approximately SEK 56.2 million before issue costs (the “Rights Issue”). The Company has received subscription commitments from existing shareholders, including Linc and MAC Clinical Research, as well as members of the board of directors and management, amounting to approximately SEK 15 million, corresponding to approximately 27 percent of the Rights Issue. The Company has furthermore entered into guarantee undertakings with existing shareholders and external investors which, in aggregate, amount to approximately SEK 33 million, corresponding to approximately 59 percent of the Rights Issue. Consequently, the Rights Issue is covered by subscription commitments and guarantee undertakings amounting to approximately SEK 48 million, corresponding to approximately 86 percent of the Rights Issue.

Initiator Pharma A/S, a clinical-stage biotech company, today announced the expansion of its program in Female Sexual Dysfunction (FSD) to include vulvodynia, a severe chronic pain condition affecting approximately 10% of women worldwide. A Phase 2a clinical proof-of-concept study is expected to start in H2 2025, evaluating pudafensine as a potential treatment for vulvodynia. Funding of the Phase 2a study is secured through a convertible credit agreement with MAC Clinical Research worth up to GBP 2.5 million. The agreement gives MAC Clinical Research the right to convert the credit into Initiator Pharma shares upon the full completion of the planned Phase 2a study at a 40% premium to the TERP in a separately announced rights issue.